Insights

Gathering insights about Jaguar…

Similar companies to Jaguar

Jaguar Tech Stack

Jaguar uses 8 technology products and services including Decibel, Facebook Pixel, Cloudflare, and more. Explore Jaguar's tech stack below.

Decibel
Analytics
Facebook Pixel
Analytics
Cloudflare
Content Management System
Google Font API
Font Scripts
Modernizr
Javascript Libraries
List.js
Javascript Libraries
Cloudflare Bot Management
Security
Apache
Web Servers

Media & News

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient
As recently announced , initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome patient by up to 12.5% The first two patients in this IIT were taken off crofelemer after 12 weeks of treatment for a period intended to last 30 days, per the study protocol, but were promptly placed back on daily crofelemer treatment because their symptoms worsened Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's intestinal failure products, resulting in non-dilutive funding for Jaguar SAN FRANCISCO, CA / ACCESS Newswire / June 30, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that initial proof-of-concept results show that a novel liquid formulation of crofelemer reduced the required total parenteral nutrition (TPN) and supplementary intravenous fluids in a third intestinal failure patient. This is the second pediatric patient with intestinal failure due to the orphan disease short bowel syndrome (SBS-IF) who was treated with crofelemer.
Jun 30, 2025 | www.accessnewswire.com
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value SAN FRANCISCO, CA / ACCESS Newswire / June 26, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX ) ("Jaguar" or "the Company"), announced today that its Board of Directors has unanimously authorized the Company to include cryptocurrency as a treasury reserve asset. "Cryptocurrencies continue to gain investor attention and acceptance as a major asset class.
Jun 26, 2025 | www.accessnewswire.com
Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs
Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs Jaguar is exploring the possibility of approval of Canalevia for treatment of general diarrhea in dogs in the EU based on the statistically significant data from a completed study Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia to regulatory approval and commercialization for general diarrhea globally SAN FRANCISCO, CA / ACCESS Newswire / June 25, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), under its Jaguar Animal Health tradename for the veterinary market, today announced that the company plans to pursue approval from the European Medicines Agency's (EMA) Committee for Veterinary Medicinal Products (CVMP) for Canalevia (crofelemer delayed-release tablets) in the European Union for treatment of general diarrhea in dogs. Canalevia, under the name Canalevia-CA1, is conditionally approved by the U.S. Food and Drug Administration (FDA) as a prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
Jun 25, 2025 | www.accessnewswire.com
Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026
Company's CEO, board members, other C-suite members, and institutional and accredited investors are participants in the extension of the bridge financing SAN FRANCISCO, CA / ACCESS Newswire / June 24, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX ) ("Jaguar" or "the Company"), announced today that the maturity date has been extended from June 30, 2025 to January 30, 2026 for approximately $2.57 million aggregate principal amount of convertible promissory notes originally issued by the Company as part of the previously announced $3.448 million bridge financing that closed on March 31, 2025. Prior to the extension, five investors converted $0.866 million (including accrued interest) of the original bridge financing into equity in the Company.
Jun 24, 2025 | www.accessnewswire.com
Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer
Enrollment in company's first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached approximately 25% As recently announced , initial proof-of-concept results of the ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in patients with intestinal failure due to MVID and short bowel syndrome by up to 27% and 12.5% respectively; data from the third patient enrolled is expected Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's intestinal failure products, resulting in non-dilutive funding for Jaguar SAN FRANCISCO, CA / ACCESS Newswire / June 23, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) (Jaguar) today provided updates on the company's orphan disease intestinal failure program. Jaguar, through Jaguar family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics, is currently supporting two independent proof-of-concept investigator-initiated trials (IITs), and conducting two placebo-controlled Phase 2 studies, of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, in patients with intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) in the United States, European Union, and/or Middle East/North Africa regions.
Jun 23, 2025 | www.accessnewswire.com
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 17, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Wednesday, June 18, 2025 at the Emerging Growth Conference. Participation Instructions for Jaguar's Virtual Presentation at the Emerging Growth Conference When: Wednesday, June 18, 2025 from 9:40 - 10:10 AM Eastern Time Where: Online (Click Here) Registration link for conference: Click Here Replay: An archived webcast of the presentation will be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel.
Jun 17, 2025 | www.accessnewswire.com
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of crofelemer from CID to treatment of general, non-infectious diarrhea in dogs Jaguar in discussions with potential partners to license and fund development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S. and/or globally Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs SAN FRANCISCO, CA / ACCESS Newswire / June 11, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), under its Jaguar Animal Health tradename for the veterinary market, today announced that the first study site has been established for Jaguar's field study of Canalevia-CA1, Jaguar's U.S. Food and Drug Administration (FDA) conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Jaguar has two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) in dogs and to expand the indication of crofelemer from CID in dogs to treatment of general, non-infectious diarrhea in dogs.
Jun 11, 2025 | www.accessnewswire.com

Jaguar's Email Address Formats

Jaguar uses at least 1 format(s):

Jaguar Email Formats	Example	Percentage
F.Last@jaguar.com	J.Doe@jaguar.com	64%
FLast@jaguar.com	JDoe@jaguar.com	20%
First.Last@jaguar.com	John.Doe@jaguar.com	15%
FL@jaguar.com	JD@jaguar.com	1%

Frequently Asked Questions

Where is Jaguar's headquarters located?

Jaguar's main headquarters is located at Abbey Road Coventry, CV3 4LF United Kingdom. The company has employees across 5 continents, including EuropeNorth AmericaAsia.

What is Jaguar's phone number?

You can contact Jaguar's main corporate office by phone at

+1-305-444-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Jaguar's stock symbol?

Jaguar is a publicly traded company; the company's stock symbol is JAGX.

What is Jaguar's official website and social media links?

Jaguar's official website is jaguar.com and has social profiles on LinkedIn.

How much revenue does Jaguar generate?

As of June 2025, Jaguar's annual revenue reached $304K.

What is Jaguar's NAICS code?

Jaguar's NAICS code is 3361 - Motor Vehicle Manufacturing.

How many employees does Jaguar have currently?

As of June 2025, Jaguar has approximately 10K employees across 5 continents, including EuropeNorth AmericaAsia. Key team members include Chief Executive Officer: T. M.Director Of Design: I. C. C.Director: E. A.. Explore Jaguar's employee directory with LeadIQ.

What industry does Jaguar belong to?

Jaguar operates in the Motor Vehicle Manufacturing industry.

What technology does Jaguar use?

Jaguar's tech stack includes DecibelFacebook PixelCloudflareGoogle Font APIModernizrList.jsCloudflare Bot ManagementApache.

What is Jaguar's email format?

Jaguar's email format typically follows the pattern of . Find more Jaguar email formats with LeadIQ.

Jaguar

Motor Vehicle ManufacturingCoventry, United Kingdom10001+ Employees

Copy nothing.

Company Overview

Headquarters: Abbey Road Coventry, CV3 4LF United Kingdom
Phone number: +1-305-444-****
Website: jaguar.com
Stock Symbol: JAGX
NAICS Code: 3361 - Motor Vehicle Manufacturing
Employees: 10001+

Media & News

Funding & Financials

$10M
Jaguar's revenue is in the range of $10M

Funding & Financials

$10M
Jaguar's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Jaguar

Maserati

Lexus

Ferrari

Tesla Motors

Jaguar Tech Stack

Media & News

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Jaguar's Email Address Formats

Frequently Asked Questions

Where is Jaguar's headquarters located?

What is Jaguar's phone number?

What is Jaguar's stock symbol?

What is Jaguar's official website and social media links?

How much revenue does Jaguar generate?

What is Jaguar's NAICS code?

How many employees does Jaguar have currently?

What industry does Jaguar belong to?

What technology does Jaguar use?

What is Jaguar's email format?

Jaguar

Company Overview

Media & News

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?